跳至主要内容
临床试验/ISRCTN13866189
ISRCTN13866189进行中(未招募)3 期

Metformin impact on maternal and infant cardiometabolic health

niversity of Manchester0 个研究点目标入组 225 人开始时间: 2021年2月15日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
225

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Singleton pregnancy between 6+0 and 30+0 weeks’ gestation inclusive
  • 2. Aged 18 years or over and willing and able to give informed consent
  • 3. Diagnosis of diabetes in pregnancy
  • 3.1. Type 2 diabetes diagnosed before pregnancy and requiring pharmacological treatment
  • 3.2. Type 2/GDM diagnosed <24 weeks’ gestation: abnormal glucose tolerance test, abnormal HBGM and/or HbA1C =42mmol/L
  • 3.3. GDM (diagnosed 24-30 weeks): HbA1C =39mmol/L and/or abnormal glucose tolerance test
  • 4. Abnormal HBGMb (=30 weeks)
  • 5. Presence of at least one risk factor for placental disease
  • 5.1. BP =130 and/or =80mmHg (clinic blood pressure)
  • 5.2. Pulse wave velocity = 9m/s
  • 5.3. Age =35 years
  • 5.4. Nulliparous
  • 5.5. Pre-eclampsia and/or small for gestational age (<10th centile) in a prior pregnancy
  • 5.6. Mean uterine artery PI =95th centile
  • 5.7. Placental growth factor <10th centile
  • 6. EFW =50th centile (if =22 weeks)

排除标准

  • 1. Medical contraindication to metformin
  • 2. Known diagnosis of Type 1 diabetes
  • 3. Multifetal pregnancy
  • 4. Prior pregnancy complicated by shoulder dystocia

研究者

发起方
niversity of Manchester

相似试验